2012
DOI: 10.1128/aac.00488-12
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Identification andIn VitroResponse to Antifungal Drugs of Clinical Isolates of Exserohilum

Abstract: ABSTRACTExserohilumis an agent of human and animal mycoses. Although classification has been based on a few subtle morphological differences, three species of clinical interest have been traditionally accepted. In this study, by using a multigene sequence analysis, we have demonstrated that Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
35
1

Year Published

2013
2013
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 44 publications
(37 citation statements)
references
References 24 publications
1
35
1
Order By: Relevance
“…than those recently reported for E. rostratum (28), but these drugs were still considered to demonstrate good activity by clinical experts (30). The itraconazole and posaconazole range reported by da Cunha and colleagues (28) was Ͻ0.03 to 0.125 g/ml, while for voriconazole it was slightly higher at Ͻ0.03 to 1 g/ml.…”
Section: Discussionmentioning
confidence: 61%
See 1 more Smart Citation
“…than those recently reported for E. rostratum (28), but these drugs were still considered to demonstrate good activity by clinical experts (30). The itraconazole and posaconazole range reported by da Cunha and colleagues (28) was Ͻ0.03 to 0.125 g/ml, while for voriconazole it was slightly higher at Ͻ0.03 to 1 g/ml.…”
Section: Discussionmentioning
confidence: 61%
“…All of the E. rostratum isolates grew well at 37°C and produced conidia within 8 to 12 days on V8 juice agar and within 2 weeks on Pablum agar. Conidia had 6 to 12 distosepta, with an average of 10, and displayed a prominent hilum, making these isolates most similar morphologically to Exserohilum longirostratum, a species that has recently been placed into conspecificity with E. rostratum (28).…”
Section: By 14mentioning
confidence: 99%
“…Similar to other azoles, there is an extensive list of medications that are contraindicated or should be given with caution when coadministered with voriconazole (11). Compared to voriconazole, the potential advantage of posaconazole and itraconazole is based largely on marginally better in vitro activity of these two agents (12,13). This potential advantage over voriconazole could be negated by several factors, including much poorer oral absorption, unpredictable pharmacokinetics, and the unavailability of an intravenous formulation.…”
mentioning
confidence: 99%
“…Although Clinical and Laboratory Standards Institute interpretive breakpoints have not been established for Exserohilum spp., da Cunha et al 9 have recently tested 34 clinical isolates of E. rostratum. In comparison with their results for amphotericin B (MIC range o0.03-0.125 mg/ml), itraconazole (o0.03-0.125 mg/ml), voriconazole (o0.03-1 mg/ml), micafungin (0.03 to 416 mg/ml), the MICs for amphotericin B (0.06 mg/ml) and micafungin (0.03 mg/ml) of our isolate are similar.…”
Section: Discussionmentioning
confidence: 99%